Palvella Therapeutics (PVLA) Operating Margin: 2014-2024
Historic Operating Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to 2,412.15%.
- Palvella Therapeutics' Operating Margin rose 138167.00% to 2,412.15% in Q4 2024 from the same period last year, while for Dec 2024 it was -1,482.12%, marking a year-over-year decrease of 145447.00%. This contributed to the annual value of 3,277.91% for FY2024, which is 330563.00% up from last year.
- Per Palvella Therapeutics' latest filing, its Operating Margin stood at 2,412.15% for Q4 2024, which was up 4.83% from 2,300.91% recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Operating Margin registered a high of 2,412.15% during Q4 2024, and its lowest value of -3,318.87% during Q1 2024.
- In the last 3 years, Palvella Therapeutics' Operating Margin had a median value of -66.70% in 2022 and averaged 70.82%.
- Over the last 5 years, Palvella Therapeutics' Operating Margin had its largest YoY gain of 236,140bps in 2024, and its largest YoY loss of 254,718bps in 2024.
- Over the past 5 years, Palvella Therapeutics' Operating Margin (Quarterly) stood at -661.21% in 2020, then surged by 53,094bps to -130.27% in 2021, then slumped by 6,677bps to -197.04% in 2022, then soared by 122,753bps to 1,030.48% in 2023, then soared by 138,167bps to 2,412.15% in 2024.
- Its last three reported values are 2,412.15% in Q4 2024, 2,300.91% for Q3 2024, and -3,318.87% during Q1 2024.